Brokers Set Expectations for TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Tango Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($1.58) per share for the year. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share.

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $12.20.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX traded down $0.36 during mid-day trading on Wednesday, hitting $4.69. The company had a trading volume of 2,443,774 shares, compared to its average volume of 1,476,064. The business's 50-day simple moving average is $2.02 and its 200-day simple moving average is $2.40. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02. The firm has a market cap of $508.37 million, a P/E ratio of -3.97 and a beta of 1.24.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd acquired a new position in Tango Therapeutics in the fourth quarter worth about $33,000. Stonebrook Private Inc. acquired a new position in Tango Therapeutics in the fourth quarter worth about $34,000. Ameriprise Financial Inc. acquired a new position in Tango Therapeutics in the fourth quarter worth about $35,000. Sherbrooke Park Advisers LLC acquired a new position in Tango Therapeutics in the fourth quarter worth about $38,000. Finally, Squarepoint Ops LLC acquired a new position in Tango Therapeutics in the fourth quarter worth about $40,000. Institutional investors and hedge funds own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.